Merck & Co Inc (LTS:0QAH)
$ 131.3 0 (0%) Market Cap: 249.37 Bil Enterprise Value: 272.91 Bil PE Ratio: 20.67 PB Ratio: 5.61 GF Score: 81/100

Seattle Genetics Inc Discussion of Oncology Collaborations with Merck & Co Inc - Conference Call Transcript

Sep 14, 2020 / 01:00PM GMT
Release Date Price: $81.71
Operator

Good day, everyone. And welcome to the Seattle Genetics conference call to discuss its oncology collaborations with Merck. (Operator Instructions) Please also note today's event is being recorded. And at this time, I'd like to turn the conference call over to Ms. Peggy Pinkston, Vice President of Investor Relations. Ma'am, please go ahead.

Peggy Pinkston
Seattle Genetics, Inc. - VP of IR & Executive Director of Corporate Communications

Thank you, operator, and good morning, everyone. I'm pleased to welcome you to today's conference call to discuss the joint announcement with Merck this morning regarding our collaborations on ladiratuzumab vedotin and TUKYSA.

I'm joined today by Clay Siegall, President and Chief Executive Officer; Todd Simpson, Chief Financial Officer; and Roger Dansey, Chief Medical Officer. Following Clay's prepared remarks, we'll open the line for your questions.

Today's conference call will include forward-looking statements regarding future or anticipated events and results, including the anticipated closing of Merck

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot